(PharmaNewsWire.Com, May 14, 2020 ) The global in-vitro toxicology testing market size is projected to reach USD 12.7 billion by 2024 from USD 8.1 billion in 2019, growing at a CAGR of 9.3%. The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this market. Also, the increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant opportunities for market growth in the coming years.
Thermo Fisher Scientific Inc. (US), Covance (US), Bio-Rad Laboratories, Inc. (US), GE Healthcare (US), Eurofins Scientific SE (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Cyprotex (UK), SGS S.A. (Switzerland), QIAGEN N.V. (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US) are some key players in this market. These companies are focusing on increasing their presence in high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.
Thermo Fisher Scientific was one of the leading players in the in-vitro toxicology testing market in 2018. The company is a global manufacturer of analytical instruments, laboratory equipment, software, consumables, reagents, and services for the in-vitro toxicology testing market. Owing to its strong sales and distribution network, the company has a significant global footprint. The company leverages the advantage of three well-established brands—Thermo Scientific, Fisher Scientific, and Unity Lab Services. In February 2014, Thermo Fisher acquired Life Technologies (US), thereby adding another brand name to its business. Under the four brands mentioned above, the company has a robust product portfolio for instruments, reagents, and services for life science research.
Merck is a leading science and technology company with a strong global presence in more than 120 countries. The company has a portfolio of more than 300,000 life science products that support a broad customer base. Merck majorly focuses on expansions in key geographies to increase its customer base. The firm focuses explicitly on the high-growth Asia Pacific region to increase its market share and revenue. In the last three years, the firm opened life science centers in China, India, South Korea, and Singapore to facilitate the supply of its products in the region. Targeted acquisitions to complement or boost its strengths form another key strategy for the company.
Eurofins Scientific is a key competitor in the in-vitro toxicology testing market, offering a unique range of analytical testing products and services. The company has an elaborate service portfolio and a strong product profile in ADME testing. It offers over 100 assays for profiling drug toxicity in the in-vitro toxicology testing market. Eurofins aims to provide quality services with high levels of safety in all operating markets. The company is strengthening its competitive advantage through consistent acquisitions in different regions.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
